Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

Background To compare the clinical efficacy of New York Esophageal squamous cell carcinoma-1 (NY-ESO-1) vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in a randomized, double-blind phase II study in participants with fully resected melanoma at high risk of recurrence.Methods Participants w...

Full description

Saved in:
Bibliographic Details
Main Authors: John F Thompson, Peter Hersey, Michael Millward, Paul Nathan, Weisan Chen, Ralph Venhaus, Andreas Behren, Cyril Fisher, Jonathan S Cebon, Martin Gore, Ian D Davis, Grant A McArthur, Euan Walpole, Mark Smithers, Vincenzo Cerundolo, P Rod Dunbar, Duncan MacGregor, Michael P N Findlay, T R Jeffry Evans, Jeremy Marsden, Angus G Dalgleish, Pippa G Corrie, Marples Maria, Margaret Brimble, Geoff Williams, Sintia Winkler, Heather M Jackson, Liliana Endo-Munoz, Candani S A Tutuka, Lloyd J Old, Dennis Haack, Eugene Maraskovsky
Format: Article
Language:English
Published: BMJ Publishing Group 2020-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000410.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/1/e000410.full

Similar Items